Report from the 62nd American Society of Hematology Annual Meeting — Malignant Hematology

Highlights of the latest research

Presenters at the recent meeting of the American Society of Hematology (ASH; December 5–8, 2020; all virtual) reported the latest research in hematology. Here, NEJM Journal Watch Oncology and Hematology Associate Editor Dr. Michael E. Williams describes the key findings in hematologic malignancies. The original abstracts can be found on the ASH website.

Support for Fixed-Duration Treatment in Patients with Undetectable Minimal Residual Disease in CLL/SLL

Christine Judge

Results from the phase 2 CAPTIVATE study of ibrutinib plus venetoclax (Ibr + Ven) as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) show that fixed-duration treatment allows for treatment-free remission periods in patients with undete…

Authors

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee